Brief: Kalvista Pharmaceuticals Announces UK MHRA Approval Of Ekterly (Sebetralstat)
15/07/2025 21:44
July 15 (Reuters) - Kalvista Pharmaceuticals Inc KALV.O: KALVISTA PHARMACEUTICALS ANNOUNCES UK MHRA APPROVAL OF EKTERLY® (SEBETRALSTAT), FIRST AND ONLY ORAL ON-DEMAND TREATMENT FOR HEREDITARY ANGIOEDEMA KALVISTA PHARMACEUTICALS INC - EKTERLY MEETS MHRA ORPHAN DESIGNATION CRITERIA KALVISTA PHARMACEUTICALS INC - EKTERLY AWARDED 10 YEARS MARKET EXCLUSIVITY IN UK Source text: ID:nBw4kGcq0a Further company coverage: KALV.O
Recent news on Kalvista Pharmaceuticals
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 08:36 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Seagate, GE Healthcare, Bloom Energy